BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 29, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 6/26 cls
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) Hapoalim Raghuram Selvaraju New Market outperform 9% $30.34
Selvaraju set a $33 target. He expects approval in 4Q09 of the company's BLA for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture. The injectable form of collagenase has an Aug. 28 PDUFA date. Auxilium has exclusive rights to the product from BioSpecifics Technologies Corp. (NASDAQ:BSTC).
Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA) Piper Jaffray Edward Tenthoff...

Read the full 487 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >